GenSight Biologics has successfully completed a fundraising of €1 million, supported by existing shareholders.
Amount Raised
€1 Million
Round Type
Post-IPO Equity
ParisBiotechnologyHealth CareTherapeuticsBiopharmaDescription
GenSight Biologics, a biopharmaceutical company specializing in innovative gene therapies, has announced the successful completion of a fundraising of €1 million. This fundraising was backed by its existing shareholders. The announcement follows a previous announcement made on October 8, 2026. The company continues to focus on developing treatments for neurodegenerative retinal diseases.
Quick answer
GenSight Biologics raised €1 Million in a Post-IPO Equity round, dated October 16, 2026. GenSight Biologics is based in Paris, Ile-de-France, France.
- How much did GenSight Biologics raise?
- GenSight Biologics raised €1 Million in a Post-IPO Equity round on October 16, 2026.
- What does GenSight Biologics do?
- GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
- Where is GenSight Biologics based and how big is it?
- GenSight Biologics is based in Paris, Ile-de-France, France. Fundz records about 26 employees.
- Who are the decision-makers at GenSight Biologics?
- Fundz holds 4 contacts at GenSight Biologics, including the Chief Technology Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as GenSight Biologics that raised within 45 days of this round, from Fundz verified event records.
- BioVie raised $4.7M (Post-IPO Equity) on November 6, 2026.
- Quanta Therapeutics raised an undisclosed amount (Series D) on October 24, 2026.
- Disc raised $422M (Post-IPO Equity) on October 20, 2026.
- Acta Pharmaceuticals raised $24M (Seed) on October 15, 2026.
- Os Therapies raised $7.2M on October 15, 2026.
- Ensho Therapeutics raised $7.3M on October 2, 2026.
Who to call at GenSight Biologics, and when
A new round usually means GenSight Biologics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day GenSight Biologics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GenSight Biologics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GenSight Biologics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GenSight Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
GenSight Biologics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.